Clinical trial · Observational
Hypofractionated Radiotherapy for Prostate Cancer
Hypofractionated Radiotherapy for Prostate Cancer in 20 Sessions
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiotherapy is a standard definitive treatment for men with localized prostate cancer. Recent improvements in technology allow high doses of radiation to be delivered to the prostate in less days with lower doses to surrounding healthy tissues, trying to reduce side effects. This study is being proposed to evaluate the use of moderate hypofractionated volumetric radiotherapy in localized prostate cancer patients and assessing treatment -related later adverse events using the CTCAE 4.0
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hypofractionated volumetric radiotherapy in 20 fractions | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Treatment-related adverse events assessed by CTCAE v4.0
- timeFrame
- Participants should be followed continuously, for the duration of 10 years
- description
- Number of patients with treatment-related adverse events as assessed by Common Toxicity Criteria for Adverse Effects v4.0
Secondary outcomes (1)
- measure
- Biochemical relapse free survival
- timeFrame
- Participants should be followed continuously, for the duration of 10 years
- description
- By Phoenix definition ( Nadir + 2 ng/ml) Participants should be followed at baseline and follow-up, for the duration of 10 years
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologic confirmation of adenocarcinoma of the prostate by biopsy * Performance Status 0-2 * Signed informed consent form Exclusion Criteria: * Positive lymph-nodes or metastatic disease from prostate cancer on imaging studies * Anticoagulant treatment, individual assessment of antiplatelet therapy * Previous pelvic radiotherapy * Previous surgery for prostate cancer * Previous transurethral resection of the prostate * History of Crohn's Disease or Ulcerative Colitis * Antecedents of rectal fistulas in the last 10 years * Previous significant urinary obstructive symptoms * Previous chemotherapeutic treatments * Non-compliance with constraints established in this protocol (see special section
References
Publications (0)
Data not yet available